Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Pharma in Focus Jobs
Latest News
Chem Warehouse case savages Sigma share price
Wholesalers: Sigma's share price drops nearly 40 per cent and stays low for a second day as its case against Chemist Warehouse is mapped out in the Supreme Court of Victoria.
AFT predicts uplift from codeine void
Companies: Australasian outfit AFT Pharma has reported a full-year loss but expects a return to profit partly on the back of Australian sales of painkiller Maxigesic as codeine-containing meds go on script.
Time to disrupt pharma marketing
Marketing: Forget science, persuasion, USP and proposition and try a less rational, more emotive pitch says Leif Stromnes from DDB Australia.
US pounds NZ's Pharmac
Views from Abroad: Annual US trade report again slams NZ's pharmaceutical management agency over its pricing and reimbursement system while Australia comes out unscathed... for now.
AZ pipeline under scrutiny
Pipeline: AstraZeneca's pipeline is under scrutiny - and for some analysts found wanting - after the British pharma giant announced it was selling Euro rights to genericised heart failure drug Seloken, branded in Australia as Toprol-XL.
Most Popular
Is the dinner meeting dead?
Med Ed: Maybe not but it pays to beware of the 'knife and fork brigade' and widen your options, a marketing seminar has heard.
Trust survey delivers shock result for Aussie pharma
Reputation: In marked contrast to other parts of the world, public trust in pharma in Australia has fallen sharply says a new global survey.
Your pharmacist is a 'govt agent'
Retail: As Health Minister Greg Hunt considers the King pharmacy review, review chair Professor Stephen King says pharmacists are best seen as 'agents of government'.
Novartis works on compliance after string of scandals
Compliance: Accusations and charges of bribery in South Korea, Greece, China and Turkey that have led to fines of close to US$75m have Novartis' signalling a new approach to compliance.
Hidden advantage for generics in bigger PBS cuts
Budget 2017-18: Bigger statutory price cuts announced in the budget increase the financial risk for pharmacos in defending patents, meaning generic drugs could come to market more quickly, say lawyers.
Review threatens PBAC integrity: MSD
Reimbursement: MSD has responded to the revised draft of the PBS post-market review of ezetimibe by alleging it could undermine the integrity of the PBAC and put Health Minister Greg Hunt in a 'difficult position'.
Forced switch to biosim OK says study
Biosimilars: As Australia's budget pushes for greater biosimilar uptake, a new large Danish study shows switching from Remicade to a biosimilar has no negative effect on patients.
AZ calls for pharma chapter in Aust/UK FTA
Brexit: AZ has provided a pharma-specific wish list to the parliamentary committee considering Australia and Britain's post-Brexit trade relationship.
Symbion owner scores hospital coup
Mergers: Symbion owner EBOS continues its Australian expansion, buying leading hospital pharmacy services operator HPS for $154m.
Shire could bring HAE blocker to Aust
Pipeline: Shire is 'exploring opportunities' for bringing a new drug, which has shown promise in preventing a rare genetic blood disorder, to Australia.
MSD v PBAC: it's all about the data
It might have been short but MSD's statement on the revised draft report of the post-market review of ezetimibe spoke volumes on how treatment of PBS data can skew conclusions to potentially alarming effect.
Approvals Action
New hope for metabolic disease
Alexion's orphan therapy Kanuma has been approved by the TGA for metabolic disease lysomal acid lipase deficiency.
Pipeline Monitor
Pfizer sets Xeljanz for psoriatic arthritis
Pfizer has filed Janus kinase inhibitor Xeljanz with the FDA in the hopes of a second indication in psoriatic arthritis for the star drug.
FREE Content
Events & Conferences
Pharma in Focus Jobs